Item 7.01 Regulation FD Disclosure.
As previously disclosed, on June 5, 2022, Yumanity Therapeutics, Inc., a Delaware corporation (Yumanity), entered into the Agreement and Plan
of Merger with Kineta, Inc., a Washington corporation (Kineta) and Yacht Merger Sub, Inc., a Washington corporation and wholly-owned subsidiary of Yumanity (such transaction, the Merger).
On June 17, 2022, Kineta issued a press release announcing that it presented the Phase 1/2 clinical trial design and new preclinical data supporting KVA12.1
as a potential treatment for cancer patients with advanced solid tumors at the Tumor Myeloid-Directed Therapies Summit held on June 14-16 in Boston, MA. The press release is attached hereto as Exhibit 99.1.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed filed for any purpose, and
shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act) or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such
a filing.
Important Information and Where to Find It
This communication may be deemed to be solicitation material with respect to the proposed transaction between Yumanity and Kineta. In connection with the
proposed transaction, Yumanity intends to file relevant materials with the U.S. Securities and Exchange Commission (the SEC), including a registration statement on Form S-4 that will contain a
prospectus and a proxy statement. Yumanity will mail the proxy statement/prospectus to the Yumanity stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective. Investors and securityholders of
Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transaction. This communication is not a substitute for the registration
statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transaction. Investors and securityholders may obtain free copies of the documents
filed with the SEC, once available, on Yumanitys website at www.yumanity.com, on the SECs website at www.sec.gov or by directing a request to Yumanitys Investor Relations at (212) 213-0006
ext. 331.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
Participants in the
Solicitation
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Yumanity in connection with the proposed transaction. Information about the executive officers and directors of Yumanity is set forth in Yumanitys Definitive Proxy Statement on Schedule 14A relating to the 2022
Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, will be
set forth in the proxy statement/prospectus, which will be included in Yumanitys registration statement on Form S-4 when it is filed with the SEC. You may obtain free copies of these documents as
described above.